Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajesh Kumar Soni

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
NPJ Breast Cancer|May 25, 2021
Anti-tumor effects of an ID antagonist with no observed acquired resistancePaulina M Wojnarowicz, Marta Garcia Escolano, Yun-Han Huang, et al.
Nature Neuroscience|October 15, 2024
A cross-disease resource of living human microglia identifies disease-enriched subsets and tool compounds recapitulating microglial statesJohn F Tuddenham, Mariko Taga, Verena Haage, et al.
Biorxiv : the Preprint Server for Biology|December 20, 2023
H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programsBrian Krug, Bo Hu, Haifen Chen, et al.
Cancer Cell|June 16, 2023
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunityPatricia Ho, Johannes C Melms, Meri Rogava, et al.
Cell Reports|October 3, 2019
A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular NeovascularizationPaulina M Wojnarowicz, Raquel Lima E Silva, Masayuki Ohnaka, et al.
Nature Genetics|May 18, 2026
H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programsBrian Krug, Bo Hu, Haifen Chen, et al.
Science (New York, N.Y.)|February 1, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127Skye Montoya, Jessie Bourcier, Mark Noviski, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
NPJ Breast Cancer|May 25, 2021
Anti-tumor effects of an ID antagonist with no observed acquired resistancePaulina M Wojnarowicz, Marta Garcia Escolano, Yun-Han Huang, et al.
Nature Neuroscience|October 15, 2024
A cross-disease resource of living human microglia identifies disease-enriched subsets and tool compounds recapitulating microglial statesJohn F Tuddenham, Mariko Taga, Verena Haage, et al.
Biorxiv : the Preprint Server for Biology|December 20, 2023
H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programsBrian Krug, Bo Hu, Haifen Chen, et al.
Cancer Cell|June 16, 2023
The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunityPatricia Ho, Johannes C Melms, Meri Rogava, et al.
Cell Reports|October 3, 2019
A Small-Molecule Pan-Id Antagonist Inhibits Pathologic Ocular NeovascularizationPaulina M Wojnarowicz, Raquel Lima E Silva, Masayuki Ohnaka, et al.
Nature Genetics|May 18, 2026
H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programsBrian Krug, Bo Hu, Haifen Chen, et al.
Science (New York, N.Y.)|February 1, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127Skye Montoya, Jessie Bourcier, Mark Noviski, et al.
Pageof 5